Related MeSH Hierarchy (4)
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Anemia » Anemia, Hemolytic » Anemia, Hemolytic, Congenital » Anemia, Sickle Cell
Diseases [C] » Hemic and Lymphatic Diseases [C15] » Hematologic Diseases » Hemoglobinopathies » Anemia, Sickle Cell
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Anemia, Hemolytic, Congenital » Anemia, Sickle Cell
Diseases [C] » Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] » Genetic Diseases, Inborn » Hemoglobinopathies » Anemia, Sickle Cell
Description
A disease characterized by chronic hemolytic anemia, episodic painful crises, and pathologic involvement of many organs. It is the clinical expression of homozygosity for hemoglobin S. MeSH
Hierarchy View
Subtype Terms (3)
Acute Chest Syndrome
10 drugs (9 approved, 1 experimental)
Hemoglobin SC Disease
16 drugs (10 approved, 6 experimental)
Sickle Cell Trait
1 approved drug
Approved Indicated Drugs (4)
Phase 4 Indicated Drugs (22)
Phase 3 Indicated Drugs (32)
Phase 2 Indicated Drugs (73)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
acetylcholine chloride (miochol)
allogeneic hematopoietic stem cells (Hemacord)
autologous mesenchymal stem cells
cd4+ t-cell-depleted haploidentical hematopoietic cells
haploidentical mononuclear cells
lymphocyte immune globulin, anti-thymocyte globulin (equine) (Atgam)
Other Experimental Indicated Drugs (18)
Organization Involved with Phase 4 Indications (37)
Mednax Center for Research, Education and Quality
National Heart, Lung, and Blood Institute (NHLBI)
National Institutes of Health (NIH)
National University of Ireland
Organization Involved with Phase 3 Indications (92)
Atlanta Clinical and Translational Science Institute
Case Western Reserve University
Clinical Trials and Surveys Corp
Federal University of Rio Grande do Sul
Gamble Institute of Medical Research
Hoosier Cancer Research Network
Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti
Jinja Regional Referral Hospital
Katholieke Universiteit Leuven
Maryland Medical Research Institute
Maternity and Children Hospital, Makkah
Medical University of South Carolina
Murtala Muhammed Specialist Hospital
National Institute of Neurological Disorders and Stroke (NINDS)
New York City Health and Hospitals Corporation
Pediatric Emergency Care Applied Research Network
State University of New York, Brooklyn
Steven & Alexandra Cohen Children's Medical Center, New York
Organization Involved with Phase 2 Indications (105)
Assistance Publique - Hôpitaux de Paris
Blood and Marrow Transplant Clinical Trials Network
Center for International Blood and Marrow Transplant Research
Centre Hospitalier Intercommunal Creteil
Children's Medical Center Dallas
Community Medical Center, Toms River, NJ
Hôpital universitaire Robert-Debré
La Jolla Institute for Allergy & Immunology
Los Angeles Biomedical Research Institute
Methodist Cancer Center, Houston, Texas
National Cancer Institute (NCI)
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Selexys Pharmaceuticals Corporation
Sickle Cell Disease Clinical Research Network
State University of New York, Buffalo
Organization Involved with Phase 1 Indications (34)
Organization Involved with Other Experimental Indications (17)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
